Protein Engineering Market Size

Protein Engineering Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The Protein Engineering Market is expected to reach USD 5.8 billion by 2034. This market will grow at a CAGR of 11.8% over the forecast period. The demand for engineered proteins in various applications such as drug discovery, diagnostics, and industry will drive the growth of this market. In addition, the recent developments in biotechnology, especially in synthetic biology and CRISPR technology, have made the design of the engineered proteins more efficient and precise, which will also drive the market. There are several factors that are driving the growth of the Protein Engineering Market. The growing prevalence of chronic diseases and the need for individualized medicine have increased the interest of pharmaceutical companies in the development of therapeutic proteins. In addition, the increasing focus on sustainable development has led to the development of new engineered biofuels and biodegradable materials. The major players in this market, such as Amgen, Genentech, and Merck, are involved in several strategic collaborations and joint ventures to strengthen their product offerings and expand their market presence. Recent collaborations between biotech companies and academic institutions have led to a surge in research and development activities, which will further accelerate the growth of this market.

Regional Market Size

Regional Deep Dive

In the field of the engineering of the structure of the proteins, a great development is in progress. The elaboration of the structure of the molecule is the object of intense study. The European continent is occupied with the problem of the research and the legislation of the biopharmaceuticals. The Asia-Pacific zone is developing rapidly, pushed forward by an increase in the number of research institutes and an increase in the amount of capital invested in biotechnology. The Middle East and Africa and Latin America, although developing more slowly, are also developing their biopharmaceutical capabilities and regulatory frameworks.

North America

• The American Food and Drug Administration (FDA) has recently sped up the approval of biological products, which is expected to accelerate the development of protein drugs, thus benefiting companies like Amgen and Genentech.
• Editas Medicine and CRISPR Therapeutics have taken advantage of the latest developments in CRISPR technology to develop their engineering and gene-editing capabilities.
• The National Institutes of Health has increased its support for the engineering of recombinant proteins, which will lead to a closer collaboration between academic institutions and biotech companies, which will enhance the innovation and market growth.

Europe

• The European Medicines Agency (EMEA) has adopted new guidelines for the assessment of advanced therapy medicinal products (ATMPs), which will facilitate the approval of novel biopharmaceuticals in the region.
• Roche and Novartis are investing heavily in research into the engineering of biological molecules and are concentrating on monoclonal antibodies and a personalised medicine which are both gaining a foothold in the European market.
• Among the projects supported by the European Union’s Horizon 2020 programme are those that aim to develop protein engineering technology, which is likely to promote collaboration and innovation among the member states.

Asia-Pacific

• China is a major country in the field of biological engineering, and both the government and the private sector are heavily involved in this field. WuXi AppTec and BeiGene are two of the leading companies.
• In India, the biotechnology sector is growing rapidly, thanks to the government’s policies and initiatives such as Make in India, which encourages the manufacture of biopharmaceuticals and protein therapeutics.
• The Asia-Pacific region is a growing focus of collaboration between academic institutions and biotechnology companies, which is expected to drive innovation and the development of new therapies based on therapeutic proteins.

MEA

• The United Arab Emirates has taken steps to develop its biotechnology industry, including the establishment of the Dubai Biotechnology and Research Park, which aims to attract international biotechnology companies and to promote local research.
• South Africa is promoting its biopharmaceutical industry with government support and international collaboration. This will boost the local market for genetically engineered products.
• The regulatory framework in several countries of the Middle East and Africa is being developed to support the development of biopharmaceuticals. This will create a more favourable environment for the development of new techniques in protein engineering.

Latin America

• Brazil is investing in biotechnology research, through government programmes like the Institute of Science and Technology, which aims to boost local expertise in the field of genetic engineering and attract foreign investment.
• The presence of international companies in countries like Argentina and Chile promotes the transfer of knowledge and the development of innovation in the area of genetic engineering, which should stimulate the market.
• In the field of biological products, the regulatory framework in the region is being reformed to simplify the registration process, which should encourage the development of new therapies based on proteins.

Did You Know?

“The use of artificial intelligence and machine learning is expected to increase significantly in the global market for the engineering of the biology of proteins.” — Market Research Future

Segmental Market Size

The world market for protein engineering is currently experiencing strong growth. This is due to technological advances in biotechnology and the growing demand for tailored medicines. The rise in chronic illnesses and the need for new treatment solutions are also driving the market. Supportive regulatory policies also help to create a favorable climate for research and development.

At present, the application of the technology of genetically engineered molecules is in the process of being largely developed, and Amgen and Genentech are the leaders in the biopharmaceutical industry. The main application is the development of monoclonal antibodies and the engineering of industrial enzymes. There are some notable trends that have accelerated the development of the industry, such as the sustainable development of drug manufacturing and the application of artificial intelligence to the design of proteins. The development of CRISPR and the learning of artificial intelligence will greatly promote the development of this industry.

Future Outlook

The world market for protein engineering is estimated to grow from $2.12 billion in 2025 to $5.80 billion by 2034, with a CAGR of 11.8%. This growth is driven by the rising demand for biopharmaceuticals and the development of synthetic biology and computational biology. The need for tailored therapeutics in the development of personalized medicine is expected to further promote the development of the market. The penetration of engineered therapeutics in the therapeutics market will reach about 30% by 2034, compared to about 15% in 2025. The penetration of the field will increase significantly in all areas, especially in oncology and autoimmune diseases.

CRISPR gene-editing, the use of machine learning for the prediction of protein structures, and high-throughput screening methods are likely to change the landscape of the field of molecular biology. These advances will not only increase the efficiency of the design of new drugs but also reduce the time to market for new therapeutics. Moreover, supportive regulatory frameworks and increased research funding will also facilitate the development of novel protein-based therapies. Artificial intelligence in the design and recombinant protein production process will also have an impact on the market. Collaboration between academic institutions and biotech companies will be essential to overcoming the challenges of the field of molecular biology.